Therachon Moves 'Academic Prototype' Towards Clinic

Emerging Company Profile: Switzerland-based Therachon is developing therapeutics for rare genetic pediatric diseases with a lead program in achondroplasia, also known as genetic dwarfism. CEO Luca Santarelli explains the mechanism behind lead molecule TA-46 and plans moving forward.

Emerging Company Profile Regular column feature image Version 2
Therachon CEO discusses achondroplasia program

Founded in 2014 with $40m in the bank, Therachon AG is developing TA-46 for achondroplasia, a molecule that CEO Luca Santarelli said the company evolved from an "academic prototype," created by founder Elvire Gouze, into what Santarelli hopes will be a solid industrial program, ultimately meeting the high unmet need for those suffering from genetic dwarfism.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Start-Ups & SMEs

More from Business